BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for iTeos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-21 8:27 pm Purchase | 2024-11-14 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 2,325,000 6.400% | 1,065,524 (+84.60%) | Filing |
| 2024-02-14 09:45 am Sale | 2023-12-31 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 1,259,476 3.500% | -551,359 (-30.45%) | Filing |
| 2023-02-13 6:14 pm Sale | 2022-12-31 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 1,810,835 5.100% | -118,366 (-6.14%) | Filing |
| 2022-05-02 5:02 pm Purchase | 2022-04-22 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 1,929,201 5.400% | 1,929,201 (New Position) | Filing |